Radioactive drugs carry radioactive substances that can be engineered to specifically target and kill tumor cells inside the body. In 2018, the FDA approved a radioactive drug called Lutathera to treat tumors that affect the pancreas or gastrointestinal tract. Now, scientists at the NIH led by Dr. Frank Lin are testing whether Lutathera can also be effective against rare tumors of the adrenal glands. Dr. Lin is a clinician and researcher focused on bringing radioactive drugs — also known as radionuclides — from bench to bedside. His work could accelerate the development of new therapies for patients with rare cancers who have few or no other treatment options.

Frank Lin, M.D., is a Lasker Clinical Research Scholar in the Center for Cancer Research at the NIH’s National Cancer Institute (NCI). Learn more about Dr. Lin and his research at https://irp.nih.gov/pi/frank-lin

Podden och tillhörande omslagsbild på den här sidan tillhör The Intramural Research Program of the National Institutes of Health (NIH). Innehållet i podden är skapat av The Intramural Research Program of the National Institutes of Health (NIH) och inte av, eller tillsammans med, Poddtoppen.